Practice observed

Abstract

Get full access to this article

View all access options for this article.

References

Antoniou

Pharaoh

Narod

. Average risks of breast and ovarian cancer associated with BRCQ1 or BRCA2 mutations detected on case series unselected for family history: a combined analysis of 22 studies. AMJ Hum Genet 2002; 72: 117–130.

Chen

Parmigiano

. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329–1333.

Evans

Shenton

Woodward

. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting: risk or breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer 2008; 8: 156.

Royal Marsden ICR protocol 1 management guidelines for unaffected women with a family history of breast and/or ovarian cancer, http://www.icr.ac.uk/docs/default-source/Studies/protocol-1-management-guidelines-for-unaffected-women-with-a-family-history-of-breast-and-or-ovarian-cancer (accessed 1 November 2013).

Rebbeck

Friebel

Lynch

. Bilateral prophylactic mastectomy reduces breast cancer in BRCA1 and BRCA 2 mutation carriers. The PROSE study Group. J Clin Oncol 2004; 22: 1055–1062.

NICE Clinical Guidelines CG 164 June 2013.

Armstrong

Evans

. Management of women at high risk of breast cancer. BMJ Clin Rev 2014; 348: g2756.